Improvements in Survival and Clinical Benefit With Gemcitabine as First-Line Therapy for Patients With Advanced Pancreas Cancer: A Randomized Trial - Concepedia

Concepedia

Publication | Closed Access

Improvements in Survival and Clinical Benefit With Gemcitabine as First-Line Therapy for Patients With Advanced Pancreas Cancer: A Randomized Trial

165

Citations

0

References

2023

Year

Howard A. Burris, Malcolm J. Moore, John Sahl Andersen, M R Green, Mace L. Rothenberg, Manuel Modiano, M. Christine Cripps, Russell K. Portenoy, Anna Maria Storniolo, Peter G. Tarassoff,

Journal of Clinical Oncology

Abstract

This study demonstrates that gemcitabine is more effective than 5-FU in alleviation of some disease-related symptoms in patients with advanced, symptomatic pancreas cancer. Gemcitabine also confers a modest survival advantage over treatment with 5-FU.